Home › Acute Monocytic Leukemia
Pag-aaral pangklinika para sa Acute Monocytic Leukemia na nagre-recruit sa U.S.
8 pag-aaral para sa Acute Monocytic Leukemia ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
Ayos sa estado
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT04282187Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 16, 2026 · NCT06504459Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 13, 2026 · NCT03737955Halt Aging in Survivors of Blood Cancers
Nagre-recruit
Edad 50 pataas · Lahat ng kasarian · Na-update Hul 1, 2026 · NCT07292272211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Nagre-recruitPhase 1/2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Hun 22, 2026 · NCT03670966Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Nagre-recruitPhase 2
Edad 1 hanggang 60 · Lahat ng kasarian · Na-update Mar 12, 2026 · NCT03970096A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 9, 2026 · NCT06950034Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
Nagre-recruitPhase 1
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Ene 15, 2026 · NCT06429449Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.